{"doi":"10.1289/ehp14384","title":"Lead Acetate Exposure and Cerebral Amyloid Accumulation: Mechanistic Evaluations in APP/PS1 Mice","abstract":"BACKGROUND: ) deposition. However, the nature of Pb-induced amyloid deposition and how it contributes to AD development remain unclear. OBJECTIVES: This study investigates the role of Pb in the pathogenesis of cerebral amyloid angiopathy (CAA) and whether plasminogen activator inhibitor-1 (PAI-1) contributes to this process in the APP/PS1 mouse model. METHODS: measure the level of demyelination. Finally, Y-maze and Morris water maze tests were assessed to evaluate the cognitive function of mice. RESULTS: levels in the perivascular drainage, and microglial endocytosis. Importantly, exposure to a specific PAI-1 inhibitor, tiplaxtinin, which previously was reported to lower CAA pathology in mice, resulted in less CAA-related outcomes following PbAc exposure. DISCUSSION: Our findings suggest that PbAc induced CAA/AD pathogenesis via the PAI-1 signaling in the APP/PS1 mouse model, and the inhibition of PAI-1 could be a potential therapeutic target for PbAc-mediated CAA/AD disorders. https://doi.org/10.1289/EHP14384.","journal":"Environmental Health Perspectives","year":2024,"id":445747,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":7,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9559,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":489409,"name":"Luqing L. Liu","orcid":null,"position":1,"is_corresponding":false},{"id":33583,"name":"Anna H. Wu","orcid":"0000-0003-0546-902X","position":2,"is_corresponding":false},{"id":1262135,"name":"Yongqi Yu","orcid":"0009-0005-0674-788X","position":3,"is_corresponding":false},{"id":407457,"name":"Uzay E. Emir","orcid":"0000-0001-5376-0431","position":4,"is_corresponding":false},{"id":268807,"name":"Stephen J. Sawiak","orcid":"0000-0003-4210-9816","position":5,"is_corresponding":false},{"id":486630,"name":"Paul R. Territo","orcid":"0000-0003-0460-332X","position":6,"is_corresponding":false},{"id":324301,"name":"Martin R. Farlow","orcid":"0000-0001-7897-5471","position":7,"is_corresponding":false},{"id":428969,"name":"Wei Zheng","orcid":"0000-0003-4510-9117","position":8,"is_corresponding":false},{"id":486632,"name":"Yansheng Du","orcid":"0000-0003-1457-0744","position":9,"is_corresponding":false},{"id":487604,"name":"Huiying Gu","orcid":null,"position":0,"is_corresponding":true}],"reference_count":106,"raw_metadata":null,"created_at":"2026-07-19T02:01:46.243344Z","pmid":"39412896","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}